Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Comparative Evaluation of Complement Factor D, C3, and C5 Inhibitors on Serum Bactericidal Activity Against Neisseria Meningitidis Isolates

Yongsen Zhao, Dharaben Patel, MS, Jane A Thanassi, BS, Mingjun Huang, PhD, Steven D Podos, PhD

Blood (2019) 134 (Supplement_1): 5763.

https://doi.org/10.1182/blood-2019-132253

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

David J. Araten, MD, H. Leon Pachter, Robert J Dring, Elliot Newman, Steven M Cohen

Blood (2019) 134 (Supplement_1): 4795.

https://doi.org/10.1182/blood-2019-124571

Published: 2019

Journal Articles

Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry

Christopher J. Patriquin, MDFRCPC,MSc, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Régis Peffault de Latour, MD PhD, Jun-Ho Jang, MD PhD, Saskia Langemeijer, MD PhD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Deepak Jain, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4802.

https://doi.org/10.1182/blood-2019-127005

Published: 2019

Journal Articles

Ravulizumab: a complementary option for PNH

Nathan T. Connell

Blood (2019) 133 (6): 503–504.

https://doi.org/10.1182/blood-2018-12-891499

Published: 2019

Journal Articles

Serologic Response to Meningococcal Vaccination in Patients with Cold Agglutinin Disease (CAD) in the New Era of Complement Inhibition

Ferras Alashkar, MD, Doerte Herich-Terhuerne, Nicole Preising, Ulrich Duehrsen, MD, Vogel Ulrich, MD, Alexander Röth, MD

Blood (2018) 132 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2018-99-118968

Published: 2018

Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 625.

https://doi.org/10.1182/blood-2018-99-119147

Published: 2018

Journal Articles

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Alexander Roeth, MD, Scott T. Rottinghaus, MD, Anita Hill, MBChB (Hons), PhD, Jin Seok Kim, MD PhD, Hubert Schrezenmeier, MD, Louis Terriou, MD, Alvaro Urbano-Ispizua, MD, Richard A. Wells, MD DPhil, Jun Ho Jang, MD PhD, Jeff Szer, MB, BS, FRACP, Rasha Aguzzi, MS, Eric Scott Bachman, MD PhD, Andrew I. Damokosh, PhD, Lori Shafner, PhD, Jong-Wook Lee, MD

Blood (2017) 130 (Supplement 1): 3482.

https://doi.org/10.1182/blood.V130.Suppl_1.3482.3482

Published: 2017

Journal Articles

Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry

Anita Hill, MBChB (Hons), PhD, Alexander Roeth, MD, Gérard Socié, MDPhD, Marie-Pierre Caby-Tosi, PharmD, PhD, Amanda Wilson, MPH, PhD, Philippe Gustovic, MD, Camille L. Bedrosian, MD, Robert A. Brodsky, MD

Blood (2017) 130 (Supplement 1): 3486.

https://doi.org/10.1182/blood.V130.Suppl_1.3486.3486

Published: 2017

Journal Articles

Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults

Monica Konar, Dan M. Granoff

Blood (2017) 130 (7): 891–899.

https://doi.org/10.1182/blood-2017-05-781450

Published: 2017

Includes: Supplemental data

Journal Articles

Effect of Complement Inhibition By Anti-C5 (Eculizumab) or a Small Molecule Inhibitor of Factor D (ACH-4471) on Survival of Meningococci in Blood from Vaccinated Adults

Monica Konar, PhD, Eduardo Lujan, Dan Granoff, MD

Blood (2016) 128 (22): 2429.

https://doi.org/10.1182/blood.V128.22.2429.2429

Published: 2016

Journal Articles

Serologic Response to Meningococcal Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for the Chronic Treatment with the Terminal Complement Inhibitor Eculizumab

Alexander Roeth, MD, Ferras Alashkar, MD, Doerte Herich-Terhuerne, Johannes Elias, MD, Ulrich Vogel, MD, Ulrich Duehrsen

Blood (2014) 124 (21): 4380.

https://doi.org/10.1182/blood.V124.21.4380.4380

Published: 2014

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Fadi Fakhouri, Maryvonne Hourmant, MD, Spero R. Cataland, M.D., Mario Espinosa, A. Osama Gaber, Jan Menne, Enrico Minetti, Francois Provot, Eric Rondeau, Piero Ruggenenti, Laurent Weekers, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christophe Legendre

Blood (2013) 122 (21): 2179.

https://doi.org/10.1182/blood.V122.21.2179.2179

Published: 2013

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Larry Greenbaum, MD, Marc Fila, Gianluigi Ardissino, Samhar Al-Akash, Jonathan Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole Kar, Johan Vande Walle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD

Blood (2013) 122 (21): 2191.

https://doi.org/10.1182/blood.V122.21.2191.2191

Published: 2013

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Jeffrey Szer, MBBS, Petra Muus, MD, PhD, Alexander Roeth, MD, M.O Elebute, MD, FRCP, FRCPath, Antonio M. Risitano, MD, PhD, Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, MD, PhD, Alvaro Urbano-Ispizua, MD, Carlos Manuel de Castro, III, MD, Gérard Socié, MD PhD, Robert A. Brodsky, MD

Blood (2012) 120 (21): 1260.

https://doi.org/10.1182/blood.V120.21.1260.1260

Published: 2012

Journal Articles

Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease (CAD)

Alexander Roeth, MD, Andreas Huettmann, MD, Ulrich Duehrsen, MD, Thomas Philipp, MD

Blood (2008) 112 (11): 2882.

https://doi.org/10.1182/blood.V112.11.2882.2882

Published: 2008

Journal Articles

Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections

Tom Sprong, Dirk Roos, Corry Weemaes, Chris Neeleman, Christel L. M. Geesing, Tom Eirik Mollnes, Marcel van Deuren

Blood (2006) 107 (12): 4865–4870.

https://doi.org/10.1182/blood-2005-07-2820

Published: 2006

Journal Articles

The Pattern of Interleukin-1β (IL-1β) and Its Modulating Agents IL-1 Receptor Antagonist and IL-1 Soluble Receptor Type II in Acute Meningococcal Infections

Marcel van Deuren, Johanna van der Ven-Jongekrijg, Edouard Vannier, Roelof van Dalen, Gerard Pesman, Anton K.M. Bartelink, Charles A. Dinarello, Jos W.M. van der Meer

Blood (1997) 90 (3): 1101–1108.

https://doi.org/10.1182/blood.V90.3.1101

Published: 1997

NARROW

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Comparative Evaluation of Complement Factor D, C3, and C5 Inhibitors on Serum Bactericidal Activity Against Neisseria Meningitidis Isolates

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry

Ravulizumab: a complementary option for PNH

Serologic Response to Meningococcal Vaccination in Patients with Cold Agglutinin Disease (CAD) in the New Era of Complement Inhibition

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry

Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults

Effect of Complement Inhibition By Anti-C5 (Eculizumab) or a Small Molecule Inhibitor of Factor D (ACH-4471) on Survival of Meningococci in Blood from Vaccinated Adults

Serologic Response to Meningococcal Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for the Chronic Treatment with the Terminal Complement Inhibitor Eculizumab

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Long-Term Efficacy of the Terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease (CAD)

Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections

The Pattern of Interleukin-1β (IL-1β) and Its Modulating Agents IL-1 Receptor Antagonist and IL-1 Soluble Receptor Type II in Acute Meningococcal Infections

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only